OnDemand WTP Pricing Research

Little-known Lannett tops Fortune’s fastest-growing list, thanks to big price hikes | FiercePharma

Even in the world of less-expensive generics, drugs aren’t necessarily cheap, and Lannett operates in some niches where it faces little competition, according to analysts. Lannett’s prices on cardiovascular and migraine meds more than doubled last year, with 150% and 124% increases, Fortune notes. In fact, its aggressive pricing has put Lannett under the Department of Justice’s microscope; the company has said it has received subpoenas in a federal investigation of potential collusion on pricing.

And that DOJ probe is just one risk Lannett–and its rivals–could face to their pricing freedom. U.S. lawmakers have lambasted generics makers for hiking prices and called on the Department of Health and Human Services to investigate. In a recent letter, Sen. Bernie Sanders said HHS would review quarterly prices for the top 200 generics from 2005 to 2014, where price increases topped inflation. Meanwhile, the DOJ’s investigation is widening. Allergan ($AGN) recently disclosed a subpoena issued to its generics business Actavis.

Read complete article here:

Little-known Lannett tops Fortune’s fastest-growing list, thanks to big price hikes – FiercePharma.